Cowen & Co. analyst Yaron Werber maintained a Buy rating on Stoke Therapeutics Inc (STOK) yesterday. The company’s shares closed last Monday at $30.27, close to its 52-week high of $31.76.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 10.3% and a 61.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stoke Therapeutics Inc with a $37.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.76 and a one-year low of $18. Currently, Stoke Therapeutics Inc has an average volume of 311.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver.
